Search results
Showing 1021 to 1028 of 1028 results for drug therapy
Triple therapy recommended by NICE for patients with multiple myeloma
The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE today (26 February) recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
New Strensiq deal paves way for NICE approval of life saving drug
An agreement has been reached that means more people with a rare life threatening disease can be offered an innovative new drug.
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
Behind the Headlines - Prostate cancer drug decision a 'cruel twist'
We take a closer look at media coverage that claims our prostate cancer drug decision is a 'cruel twist' for patients.
these. Our guidance says that due to a drop in the price of statins, these drugs are now cost effective at a lower clinical threshold....
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
Evidence-based recommendations on drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. This involves draining excess CSF from the brain, washing out the blood, and breaking down blood clots using drugs (fibrinolytics).
View recommendations for IPG412Show all sections
Sections for IPG412